AZI2
5-azacytidine-induced protein 2
Protein Summary
Adapter protein which binds TBK1 and IKBKE playing a role in antiviral innate immunity. Activates serine/threonine-protein kinase TBK1 and facilitates its oligomerization. Enhances the phosphorylation of NF-kappa-B p65 subunit RELA by TBK1. Promotes TBK1-induced as well as TNF-alpha or PMA-induced activation of NF-kappa-B. Participates in IFNB promoter activation via TICAM1. AZI2, or NAP1, contributes to the activation of NFKB (see MIM 164011)-dependent gene expression by activating IKK-related kinases, such as NAK (TBK1; MIM 604834) (Fujita et al., 2003 [PubMed 14560022]).[supplied by OMIM, Mar 2008]
- ENST00000334100
- ENSP00000335609
- ENSG00000163512
- ENST00000420543
- ENSP00000391696
- ENST00000457172
- ENSP00000389577
- ENST00000479665
- ENSP00000419371
- NAP1
- TBKBP2
- AZ2
- NAP1
- TILP
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
drug perturbation | 1 | ||
virus perturbation | 1 | ||
transcription factor binding site profile | 0.91 | ||
kinase perturbation | 0.84 | ||
interacting protein | 0.81 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 6.79 (req: < 5)
Gene RIFs: 5 (req: <= 3)
Antibodies: 109 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 6.79 (req: >= 5)
Gene RIFs: 5 (req: > 3)
Antibodies: 109 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 10
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0